We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Projects granted during 2014 that have a primary purpose of translational and applied research: human cancer.
Information on the waiting times of patients with suspected cancer and those subsequently diagnosed with cancer.
This AGNIR report (RCE-1) considers the scientific evidence from studies relating to power frequency EMFs, melatonin and the risk of breast cancer.
Projects granted during 2015 that have a primary purpose of translational and applied research: projects on human cancer.
The introduction of structured pre-ART care can improve the retention and management of patients with HIV
Waiting times of people referred by their GP with suspected cancer or breast symptoms and those subsequently diagnosed with and treated for cancer by the NHS in England.
Patients with a certain type of advanced or spreading non-small cell lung cancer (NSCLC) could access a new cancer therapy to help treat their condition.
This section of the website provides information on the waiting times of people referred by their GP with suspected cancer or breast symptoms and those subsequently diagnosed with and treated for cancer by the NHS in England. http://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (27 December) approved the advanced melanoma medicine Opdualag (nivolumab-relatlimab) for patients from the age of 12.
Information on the risks from low levels of ionising radiation.
Product Safety Report for Makari Naturalle Carotonic Extreme Glow Renewing Face Serum presenting a serious chemical risk.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).